Pegcetacoplan (Systemic)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Key Facts
About Apellis Pharmaceuticals
Apellis Pharmaceuticals is on a mission to develop life-changing therapies by targeting C3, the central node of the complement cascade. The company has achieved a significant milestone with three regulatory approvals in four years, validating its platform and establishing commercial capabilities. Its strategy focuses on expanding the reach of its approved C3 inhibitor, pegcetacoplan, into new indications and geographies while advancing a pipeline of novel therapies for rare, retinal, and neurological diseases.
View full company profileAbout Apellis Pharmaceuticals
Apellis Pharmaceuticals is on a mission to develop life-changing therapies by targeting C3, the central node of the complement cascade. The company has achieved a significant milestone with three regulatory approvals in four years, validating its platform and establishing commercial capabilities. Its strategy focuses on expanding the reach of its approved C3 inhibitor, pegcetacoplan, into new indications and geographies while advancing a pipeline of novel therapies for rare, retinal, and neurological diseases.
View full company profileTherapeutic Areas
Other Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
| Drug | Company | Phase |
|---|---|---|
| OMS906 | Omeros | Phase 2 |
| Empaveli (pegcetacoplan) | bioRASI | Approved |
| KP104 | Kira Pharmaceuticals | Phase 2 |
| EMPAVELI Injector | Enable Injections | Approved |
| Ruxoprubart (NM8074) | NovelMed Therapeutics | Phase 2 |
| Fabhalta® (iptacopan) | Novartis | Approved |
| NS-580/NM-8074 | Nippon Shinyaku | Phase 2 |